Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

SkinBioTherapeutics results chart a year of significant progress

The SkinBiotix platform has been developed to enhance the skin cell barrier, protect the skin and aid its regeneration
woman examining her face in the mirror
The company's - as the name suggests - is the body's biggest organ

Annual results from SkinBioTherapeutics PLC (LON:SBTX) chart a period of significant progress, including April’s listing on AIM (which brought in £4.5mln) and the demonstration of the three modes of action of its platform, SkinBiotix.

It is developing the technology as a cosmetic, a hand cream that protects against hospital-acquired infections and a treatment for eczema.

WATCH: SkinBioTherapeutics sees flagship technology take critical next step

The SkinBiotix platform has been developed to enhance the skin cell barrier, protect the skin and aid its regeneration.

The intellectual property was spun out of the University of Manchester and specifically the work of Dr Catherine O’Neill, who is now the company’s chief executive.

Made in Manchester 

SkinBio has a research agreement with the university to develop a bacterial lysate. The company is currently scaling up manufacture from the small batches it produces, it said Thursday.

The financial results for the year to June 30 showed the newly-listed business was sitting on £3.9mln as at that date. It posted a loss of £673,000, which is modest for a company in the R&D phase.

"During the year, we have demonstrated three significant properties - barrier improvement, anti-infection and repair - which form the foundations of our three development programmes. We are making good scientific headway and are starting initial discussions with partners,” said CEO O’Neill.

"Operationally, we have made a good start to the new financial year, especially with the recent news around the third party cytotoxicity testing, and we look forward to reporting on the next phase of the company's journey."

READ: SkinBioTherapeutics PLC technology passes crucial milestone after independent test

On Tuesday, the firm said its flagship technology had passed a key safety test as it updated on progress.

Its SkinBiotix cream was assessed for cellular toxicity and specifically for adverse biological reactions from mammalian cell cultures.

Three products

As mentioned above, it is developing three products that manage, protect and restore the body’s largest organ.

First cab off the rank will be the company’s cosmetic for sensitive skin, which should be properly formulated towards the end of this year, before entering human studies in the second-quarter of next.

Going into development in the third-quarter of next year is a prophylactic for healthcare acquired infections.

The company hopes to begin commercialising the protective hand cream in 2020, the same year as work begins on an eczema treatment.

The research and development group, which is focused on understanding the skin-based portion human microbiome, said it had made a number of key advances in recent months as it updated on the progress of its three programmes.

View full SBTX profile View Profile

SkinBioTherapeutics PLC Timeline

Related Articles

1513583223_shutterstock_86097949.jpg
December 18 2017
VAL201 is a treatment for metastatic prostate cancer and other solid tumours
Antibiotics
October 04 2017
US Food & Drug administration approval is yet to be granted but iclaprim, which has fast-track status, is closing in on the promised land.
cancer cells
July 12 2017
The US-based, London-listed healthcare group topped expectations with its latest results and analysts are tipping it for more success this year

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use